Crenessity CAH denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for crenessity cah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny Crenessity for CAH as "Not FDA-Approved" — and Why This Is Disputable

A "not FDA-approved" denial for Crenessity (tildacerfont) in congenital adrenal hyperplasia is most likely the result of a plan system or reviewer using outdated information. Crenessity received FDA approval for CAH; if BCBS's internal drug file has not been updated to reflect this, it may erroneously classify the drug as unapproved. This is an administrative error, not a clinical judgment, and it is among the more straightforward denial types to reverse on appeal.

Less commonly, a plan may argue that the drug is being prescribed for a use beyond the labeled indication. In either case, the appeal strategy is to place the FDA approval documentation directly in front of the reviewer.

## Federal Appeal Rights

• ACA §2719 external review: After exhausting internal appeals, you may request independent external review. The standard window is approximately four months from the final internal denial — confirm your exact deadline from the denial letter. Expedited review is available for urgent situations.
• ERISA §503: Employer-plan members are entitled to a written statement of the specific grounds on which FDA approval was disputed, and which plan provision was applied.

## Concrete Appeal Steps

1. Confirm the FDA approval status. Retrieve the current FDA label and approval summary for Crenessity from the FDA's Drugs@FDA database. Print or download the label showing the approved indication. 2. Identify the exact denial ground. Request the specific coverage policy BCBS applied. Determine whether the denial is (a) a system error treating the drug as unapproved, or (b) a claim that your use falls outside the labeled indication. 3. For a system-error denial: Submit the FDA label with a brief cover letter noting the approval date and labeled indication. Ask BCBS to reprocess the claim. 4. For an off-label claim: Obtain your prescriber's letter confirming the prescribed use matches the FDA-approved indication exactly, with the relevant diagnosis codes. 5. Gather supporting records: CAH diagnosis documentation, the prescriber's order, and relevant clinical notes. 6. File the internal appeal within the plan's stated deadline.

## Criteria-Mapping Structure

| Denial Basis | Your Documentation | |---|---| | Drug not FDA-approved | FDA label and approval documents from Drugs@FDA | | Use falls outside labeled indication | Prescriber letter confirming on-label use; diagnosis records | | Plan's drug file is outdated | Cover letter noting FDA approval date and requesting reprocessing |

Before filing, download the current Crenessity prescribing information directly from the FDA and attach it as a primary exhibit. This type of denial often resolves at the internal appeal level without needing external review.